Sintilimab plus chemo before and after surgery for advanced oral cancer
Part of Cancer clinical trials.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of mouth cancer called oral squamous cell carcinoma that is stage III or IVA and has not spread too far.
- You are willing and able to have surgery to remove the cancer.
- You have good overall health, including adequate blood counts, kidney and liver function, and no serious heart or lung problems.
- You have not had previous treatment with certain immunotherapy drugs or radiation to the head or neck area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding targeted radiation (SBRT) to a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced mouth or throat cancer. It aims to shrink the tumor more effectively before removal.
This trial tests whether adding two immunotherapy drugs (sintilimab and cetuximab) before and after surgery can improve outcomes for people with advanced mouth or throat cancer. It is for those who have not yet had treatment and whose tumors have a certain protein level (PD-L1 CPS >1).
This trial tests a combination of three drugs (adebrelimab, carboplatin, and albumin-bound paclitaxel) before surgery for people with advanced mouth cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial tests a new combination of two drugs (sacituzumab govitecan and toripalimab) given before surgery to shrink advanced oral cavity tumors. The goal is to see if this approach helps make surgery more effective and improves outcomes.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) given before surgery to treat mouth or throat cancer that has come back. The goal is to shrink the tumor and improve surgery outcomes.
This Phase 2 trial tests giving the immunotherapy drug sintilimab before surgery, along with fewer chemotherapy cycles. The goal is to shrink or control oral or throat squamous cell cancers while keeping side effects lower, before the tumor is removed.
Hear when a new Locally Advanced Oral Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.